Literature DB >> 8339262

Evidence for in situ amplification of cytotoxic T-lymphocytes with antitumor activity in a human regressive melanoma.

A Mackensen1, L Ferradini, G Carcelain, F Triebel, F Faure, S Viel, T Hercend.   

Abstract

We have derived from lymphocytes infiltrating a human regressive melanoma lesion a series of T-cell receptor alpha/beta-dependent, HLA-B14-restricted cytotoxic T-lymphocyte clones reactive against the autologous tumor. Analysis of the T-cell receptor gene expression revealed that all the clones represented a unique cell expressing a V beta 13.1/J beta 1.1 gene segment. T-cell receptor transcripts expressed in the cloned cells were compared to those present in the uncultured tumor tissue. This analysis demonstrated that the specific cytotoxic T-lymphocyte clones characterized in vitro was actually selected and amplified in vivo at the lesion site. These results provide strong evidence that effector T-cells have contributed to tumor regression.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8339262

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  31 in total

1.  In vivo selective expansion of a tumour-specific cytotoxic T-cell clone derived from peripheral blood of a melanoma patient after vaccination with gene-modified autologous tumour cells.

Authors:  Y Sun; P Möller; C Berking; E M Schlüpen; M Volkenandt; D Schadendorf
Journal:  Immunology       Date:  1999-12       Impact factor: 7.397

2.  Tumour infiltrating lymphocytes: insights into tumour immunology and potential therapeutic implications.

Authors:  K F Yoong; D H Adams
Journal:  Clin Mol Pathol       Date:  1996-10

3.  In vivo accumulation of the same anti-melanoma T cell clone in two different metastatic sites.

Authors:  M Hishii; D Andrews; L A Boyle; J T Wong; F Pandolfi; P J van den Elsen; J T Kurnick
Journal:  Proc Natl Acad Sci U S A       Date:  1997-02-18       Impact factor: 11.205

4.  A role for HLA-DO as a co-chaperone of HLA-DM in peptide loading of MHC class II molecules.

Authors:  H Kropshofer; A B Vogt; C Thery; E A Armandola; B C Li; G Moldenhauer; S Amigorena; G J Hämmerling
Journal:  EMBO J       Date:  1998-06-01       Impact factor: 11.598

Review 5.  Immunotherapy as a Potential Treatment for Chordoma: a Review.

Authors:  Shalin S Patel; Joseph H Schwab
Journal:  Curr Oncol Rep       Date:  2016-09       Impact factor: 5.075

6.  Targeting tumor-resident mast cells for effective anti-melanoma immune responses.

Authors:  Susanne Kaesler; Florian Wölbing; Wolfgang Eberhard Kempf; Yuliya Skabytska; Martin Köberle; Thomas Volz; Tobias Sinnberg; Teresa Amaral; Sigrid Möckel; Amir Yazdi; Gisela Metzler; Martin Schaller; Karin Hartmann; Benjamin Weide; Claus Garbe; Hans-Georg Rammensee; Martin Röcken; Tilo Biedermann
Journal:  JCI Insight       Date:  2019-10-03

Review 7.  Tumor-infiltrating lymphocytes: their phenotype, functions and clinical use.

Authors:  T L Whiteside; G Parmiani
Journal:  Cancer Immunol Immunother       Date:  1994-07       Impact factor: 6.968

Review 8.  Relevance of the T cell receptor for immunotherapy of cancer.

Authors:  E Weidmann; M Trucco; T L Whiteside
Journal:  Cancer Immunol Immunother       Date:  1994-07       Impact factor: 6.968

9.  T-cell Homing Therapy for Reducing Regulatory T Cells and Preserving Effector T-cell Function in Large Solid Tumors.

Authors:  Jiemiao Hu; Chuang Sun; Chantale Bernatchez; Xueqing Xia; Patrick Hwu; Gianpietro Dotti; Shulin Li
Journal:  Clin Cancer Res       Date:  2018-02-01       Impact factor: 12.531

10.  Direct evidence to support the immunosurveillance concept in a human regressive melanoma.

Authors:  A Mackensen; G Carcelain; S Viel; M C Raynal; H Michalaki; F Triebel; J Bosq; T Hercend
Journal:  J Clin Invest       Date:  1994-04       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.